Related references
Note: Only part of the references are listed.Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders
Ryan A. Wilcox et al.
BLOOD (2009)
In vivo effects of zoledronic acid on peripheral gamma delta T lymphocytes in early breast cancer patients
Daniele Santini et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+T-Cell Infiltration and Survival of Patients with Cervical Carcinoma
Rezaul Karim et al.
CLINICAL CANCER RESEARCH (2009)
γδ T Cells and the Lymphoid Stress-Surveillance Response
Adrian C. Hayday
IMMUNITY (2009)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
David Yin-Wei Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
Eszter Lazar-Molnar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer
Francesco Dieli et al.
CANCER RESEARCH (2007)
Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function
Selgo Terawaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study
Hirohito Kobayashi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells:: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens
Craig T. Morita et al.
IMMUNOLOGICAL REVIEWS (2007)
Perspectives of gamma delta T cells in tumor immunology
Dieter Kabelitz et al.
CANCER RESEARCH (2007)
Human Vγ9Vδ2 T cells:: promising new leads for immunotherapy of infections and tumors
Marc Bonneville et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
RH Thompson et al.
CANCER RESEARCH (2006)
Gamma delta T cell receptors
Y. -h. Chien et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
Sensing cell stress and transformation through Vγ9Vδ2 T cell-mediated recognition of the isoprenoid pathway metabolites
M Bonneville et al.
MICROBES AND INFECTION (2005)
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
LP Chen
NATURE REVIEWS IMMUNOLOGY (2004)
Potential of human γδ T lymphocytes for immunotherapy of cancer
D Kabelitz et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
B7-H1 pathway and its role in the evasion of tumor immunity
HD Dong et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2003)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
Requirement of species-specific interactions for the activation of human γδ T cells by pamidronatel
Y Kato et al.
JOURNAL OF IMMUNOLOGY (2003)
Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells
HJ Gober et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice
T Okazaki et al.
NATURE MEDICINE (2003)
Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues
M Ishida et al.
IMMUNOLOGY LETTERS (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Studies on the nonmevalonate terpene biosynthetic pathway:: Metabolic role of IspH (LytB) protein
F Rohdich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human γδ T cells in Escherichia coli
M Hintz et al.
FEBS LETTERS (2001)
Targeting of tumor cells for human γδ T cells by nonpeptide antigens
Y Kato et al.
JOURNAL OF IMMUNOLOGY (2001)
Vγ2Vδ2 T-cell receptor-mediated recognition of aminobisphosphonates
H Das et al.
BLOOD (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
